- 12/12/2016
- eisai presents latest data on bace inhibitor elenbecestat（e2609）at 9th clinical trials on alzheimer’s disease
- 11/30/2016
- eisai to present latest data on eribulin at 39th annual san antonio breast cancer symposium
- 11/30/2016
- eisai to present latest data on perampanel and rufinamide at 70th american epilepsy society annual meeting
- 11/14/2016
- statement regarding the results of the access to medicine index 2016
- 11/04/2016
- u.k. nice recommends anticancer agent halaven® as treatment for advanced breast cancer
- 10/20/2016
- ceo naito selected among the best-performing ceos in the world by harvard business review
- 10/17/2016
- 10/04/2016
- belviq xr® - a new once-daily formulation of belviq® for chronic weight management now available in the united states
- 09/30/2016
- eisai to initiate phase iii clinical study of anticancer agent lenvatinib as potential first-line therapy for advanced renal cell carcinoma
- 09/29/2016
- eisai to present latest data on lenvatinib and eribulin at esmo congress 2016
